Altenriet (DE)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~8 mi. (Nürtingen, Germany, +226 more cities)
facility
Studienpraxis Urologie ( Site 0309)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~12 mi. (Tübingen, Germany, +93 more cities)
facility
Universitaetsklinik fuer Urologie ( Site 0501)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~12 mi. (Tübingen, Germany, +159 more cities)
facility
Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~12 mi. (Tübingen, Germany, +163 more cities)
facility
Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0549)
condition
Bladder Urothelial Carcinoma
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~12 mi. (Tübingen, Germany, +150 more cities)
facility
Universitaetsklinikum Tuebingen - Medizinische Klinik ( Site 0401)
condition
Head and Neck Squamous Cell Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~12 mi. (Tübingen, Germany, +137 more cities)
facility
Universitaetsklinikum Tuebingen ( Site 0409)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~12 mi. (Tübingen, Germany, +127 more cities)
facility
Universitaetsklinikum Tuebingen ( Site 2108)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~12 mi. (Tübingen, Germany, +144 more cities)
facility
GSK Investigational Site
condition
Endometrial Carcinoma
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~12 mi. (Tübingen, Germany, +141 more cities)
facility
GSK Investigational Site
condition
Multiple Myeloma
drug
belantamab mafodotin
drug type
chemotherapy, +1 more type
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
city
~12 mi. (Tübingen, Germany, +142 more cities)
facility
Universitätsk+B4:O4linikum Tüb
biomarker
del(11)(q10), +27 more biomarkers
condition
Myelofibrosis
drug
imetelstat, +1 more drug
drug type
targeted therapy